Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
Eur Heart J
    September 2025
  1. GOTTHARDT M
    RNA-binding proteins as therapeutic targets in cardiac fibrosis and heart failure.
    Eur Heart J. 2025 Sep 9:ehaf644. doi: 10.1093.
    >> Share

  2. NEUEN BL, Vaduganathan M
    Glomerular filtration rate slope in heart failure: ready for prime time?
    Eur Heart J. 2025 Sep 9:ehaf643. doi: 10.1093.
    >> Share

  3. MENTE A, Miller V, Yusuf S
    Diet and heart failure: evidence is limited to make recommendations.
    Eur Heart J. 2025 Sep 9:ehaf521. doi: 10.1093.
    >> Share

  4. CREA F
    Myocarditis after COVID-19, sepsis-induced cardiomyopathy, and haemodynamic assessment of heart failure: focus on the myocardium.
    Eur Heart J. 2025;46:3315-3318.
    >> Share

  5. INKER LA, Neuen BL, McCallum W, Vaduganathan M, et al
    Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.
    Eur Heart J. 2025 Sep 4:ehaf591. doi: 10.1093.
    >> Share

  6. PEIKERT A, Fontana M, Solomon SD, Thum T, et al
    Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.
    Eur Heart J. 2025 Sep 2:ehaf524. doi: 10.1093.
    >> Share

  7. PACKER M
    Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
    Eur Heart J. 2025 Sep 2:ehaf645. doi: 10.1093.
    >> Share

  8. BUTT JH, Solomon SD, McMurray JJV
    Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial.
    Eur Heart J. 2025 Sep 1:ehaf635. doi: 10.1093.
    >> Share

    August 2025
  9. CHIMURA M, Docherty KF, Jhund PS, Yang M, et al
    Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
    Eur Heart J. 2025 Aug 31:ehaf706. doi: 10.1093.
    >> Share

  10. BORLAUG BA, Zile MR, Kramer CM, Litwin SE, et al
    HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Aug 31:ehaf663. doi: 10.1093.
    >> Share

  11. ANKER MS, Mahabadi AA, Totzeck M, Tewes M, et al
    Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
    Eur Heart J. 2025 Aug 30:ehaf705. doi: 10.1093.
    >> Share

  12. BUTLER J, Fioretti F, McMullan CJ, Anstrom KJ, et al
    Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
    Eur Heart J. 2025 Aug 30:ehaf655. doi: 10.1093.
    >> Share

  13. DOCHERTY KF, Heywood B, Bayes-Genis A, Campbell RT, et al
    Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.
    Eur Heart J. 2025 Aug 29:ehaf675. doi: 10.1093.
    >> Share

  14. MORA-AYESTARAN N, Ochoa JP, Gomez-Gonzalez C, Navarro-Penalver M, et al
    Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure.
    Eur Heart J. 2025 Aug 29:ehaf605. doi: 10.1093.
    >> Share

  15. GUALANDRO DM, Masip J, Halvorsen S, Price S, et al
    Acute heart failure in non-cardiac surgery.
    Eur Heart J. 2025 Aug 21:ehaf559. doi: 10.1093.
    >> Share


  16. Correction to: Telemonitoring for heart failure: a meta-analysis.
    Eur Heart J. 2025 Aug 21:ehaf509. doi: 10.1093.
    >> Share

  17. ABDIN A, Sawan N, Katbeh A
    Uniting for heart failure awareness in Syria.
    Eur Heart J. 2025 Aug 21:ehaf500. doi: 10.1093.
    >> Share

  18. CREA F
    Comprehensive update on heart failure and cardiomyopathies: from epidemiology to mechanisms and management.
    Eur Heart J. 2025;46:3027-3031.
    >> Share

  19. SEGAN L, Kistler PM, Nanayakkara S, Taylor A, et al
    Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.
    Eur Heart J. 2025 Aug 12:ehaf563. doi: 10.1093.
    >> Share

  20. ADAMO M, Pagnesi M, Ajmone Marsan N, Bauersachs J, et al
    Heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation: a holistic approach.
    Eur Heart J. 2025 Aug 1:ehaf480. doi: 10.1093.
    >> Share

    July 2025
  21. KOBAYASHI M, Bayes-Genis A, Duarte K, McMurray JJV, et al
    Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.
    Eur Heart J. 2025 Jul 30:ehaf457. doi: 10.1093.
    >> Share


  22. Correction to: Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
    Eur Heart J. 2025 Jul 24:ehaf512. doi: 10.1093.
    >> Share

  23. GIANNAKOULAS G, Farmakis IT, Hobohm L, Verbrugge FH, et al
    Acute right ventricular failure: pathophysiology, aetiology, assessment, and management.
    Eur Heart J. 2025;46:2520-2535.
    >> Share

  24. CREA F
    Heart failure: evolving management and new therapeutic targets.
    Eur Heart J. 2025;46:2359-2363.
    >> Share

  25. HEIMERL M, Erschow S, Muller-Olling M, Manstein DJ, et al
    Cardiac dysfunction related to cardiac mRNA and protein traffic impairment due to reduced unconventional motor protein myosin-5b expression.
    Eur Heart J. 2025;46:2437-2454.
    >> Share

    June 2025
  26. LI Y, Wang Y, Zhang C
    Electrical storm and refractory heart failure necessitating left ventricular assist device in ischaemic cardiomyopathy with apical aneurysm.
    Eur Heart J. 2025 Jun 16:ehaf403. doi: 10.1093.
    >> Share

  27. ZEDER K, Mak S, Galie N, Rosenkranz S, et al
    Right heart catheterization in heart failure: indications, interpretation, and pitfalls.
    Eur Heart J. 2025 Jun 16:ehaf322. doi: 10.1093.
    >> Share

  28. LINDE C, Packer M, Bauersachs J
    Great debate: ablation of atrial fibrillation should be performed in patients with heart failure with reduced ejection fraction.
    Eur Heart J. 2025 Jun 10:ehaf182. doi: 10.1093.
    >> Share

  29. RYAN M, Petrie MC, Kontopantelis E, Dodd M, et al
    Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis.
    Eur Heart J. 2025;46:2052-2062.
    >> Share

  30. LI L, Guo J, Feng J, Li T, et al
    Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.
    Eur Heart J. 2025 Jun 5:ehaf370. doi: 10.1093.
    >> Share

  31. HAYNES N, Spatz ES
    The invisible costs of heart failure: a societal toll.
    Eur Heart J. 2025 Jun 3:ehaf223. doi: 10.1093.
    >> Share

  32. CHASELING GK, Uchmanowicz I, Back M, Miro O, et al
    Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, E
    Eur Heart J. 2025 Jun 3:ehaf326. doi: 10.1093.
    >> Share

    May 2025
  33. DARVISH M, Shakoor A, Feyz L, Schaap J, et al
    Heart failure: assessment of the global economic burden.
    Eur Heart J. 2025 May 30:ehaf323. doi: 10.1093.
    >> Share

  34. TUAL-CHALOT S, Stellos K
    Unravelling heart failure cellular signalling heterogeneity with spatial transcriptomics.
    Eur Heart J. 2025 May 30:ehaf311. doi: 10.1093.
    >> Share

  35. BAUDRY G, Pereira O, Roubille F, Villaceque M, et al
    Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort.
    Eur Heart J. 2025 May 18:ehaf218. doi: 10.1093.
    >> Share

  36. LUND LH
    Heart failure: the need for cardiologist-guided follow-up to improve outcomes.
    Eur Heart J. 2025 May 18:ehaf229. doi: 10.1093.
    >> Share

  37. CREA F
    New treatments and biomarkers in heart failure, hypertrophic cardiomyopathy, and familial hypercholesterolaemia.
    Eur Heart J. 2025;46:1777-1780.
    >> Share

  38. LEE SE, Joo JH, Hwang HS, Chen SF, et al
    Spatial transcriptional landscape of human heart failure.
    Eur Heart J. 2025 May 8:ehaf272. doi: 10.1093.
    >> Share

    April 2025
  39. WIGGERS H
    Fatty acids in heart failure patients: friend or foe?
    Eur Heart J. 2025 Apr 25:ehaf247. doi: 10.1093.
    >> Share

  40. VERBRUGGE FH
    Natriuretic targets in acute heart failure with volume overload: are we misguided?
    Eur Heart J. 2025 Apr 25:ehaf243. doi: 10.1093.
    >> Share

  41. MARQUES P, Ferreira JP
    Obesity, metrics of central adiposity, and prognostic significance in heart failure with preserved and mildly reduced ejection fraction.
    Eur Heart J. 2025 Apr 25:ehaf198. doi: 10.1093.
    >> Share

  42. IVEY-MIRANDA JB, Rao VS, Cox ZL, Moreno-Villagomez J, et al
    Natriuretic response prediction equation for use with oral diuretics in heart failure.
    Eur Heart J. 2025 Apr 24:ehaf268. doi: 10.1093.
    >> Share

  43. MALGIE J, Wilde MI, Brunner-La Rocca HP, Emans ME, et al
    Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy.
    Eur Heart J. 2025 Apr 24:ehaf244. doi: 10.1093.
    >> Share

  44. DOCHERTY KF, Shen L, McMurray JJV
    Advocating for better care of patients with heart failure.
    Eur Heart J. 2025 Apr 24:ehaf224. doi: 10.1093.
    >> Share

  45. CREA F
    Focus on heart failure: sex-related differences, new light shed on SGLT2i mechanism of action, and heart failure after myocardial infarction.
    Eur Heart J. 2025;46:1457-1461.
    >> Share

  46. PEDICINO D, Volpe M
    Weekly Journal Scan: a deep insight into aldosterone antagonism across the heart failure spectrum.
    Eur Heart J. 2025 Apr 15:ehaf233. doi: 10.1093.
    >> Share

  47. VELTMANN C, Duncker D, Maier LS
    Management of de novo heart failure with reduced ejection fraction: guideline-recommended medical therapy comes first.
    Eur Heart J. 2025 Apr 9:ehaf157. doi: 10.1093.
    >> Share

  48. AKIN I, Hamdani N, El-Battrawy I
    Multimodal approaches for targeted treatment of heart failure.
    Eur Heart J. 2025 Apr 9:ehaf156. doi: 10.1093.
    >> Share

  49. XIONG G
    Post-capillary pulmonary hypertension in heart failure: addressing statistical and methodological issues in research.
    Eur Heart J. 2025 Apr 8:ehae812. doi: 10.1093.
    >> Share

  50. FAUVEL C, Lamblin N
    Post-capillary Pulmonary Hypertension in Heart Failure is associated with higher mortality and morbidity risk: not just a matter of << hasard >>.
    Eur Heart J. 2025 Apr 8:ehae814. doi: 10.1093.
    >> Share

  51. OSTROMINSKI JW, Hojbjerg Lassen MC, Claggett BL, Miao ZM, et al
    Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.
    Eur Heart J. 2025;46:1321-1331.
    >> Share

    March 2025
  52. SEN P, Sorop O, Merkus D
    Increasing heart rate in heart failure with preserved ejection fraction: a sensible way to go?
    Eur Heart J. 2025 Mar 25:ehaf109. doi: 10.1093.
    >> Share

  53. VAN LOON T, Vernooy K, Lumens J
    Rate acceleration in heart failure with preserved ejection fraction: towards different strokes for different folks.
    Eur Heart J. 2025 Mar 25:ehaf110. doi: 10.1093.
    >> Share

  54. SOUZA ACDAH, Troschel AS, Marquardt JP, Hadzic I, et al
    Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes.
    Eur Heart J. 2025;46:1112-1123.
    >> Share

  55. CREA F
    Focus on amyloidosis, peripartum cardiomyopathy, and heart failure prediction by artificial intelligence applied to ECG.
    Eur Heart J. 2025;46:987-990.
    >> Share

  56. SLIWA K, Jackson A, Viljoen C, Damasceno A, et al
    Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry.
    Eur Heart J. 2025;46:1031-1040.
    >> Share

  57. GONZALEZ-LOPEZ E, Maurer MS, Garcia-Pavia P
    Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine.
    Eur Heart J. 2025;46:999-1013.
    >> Share

  58. BOHM M, Butler J, Coats A, Lauder L, et al
    Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093.
    >> Share

    February 2025
  59. LINDBERG F, Savarese G
    Opportunities and challenges in preventing heart failure: when is risk modifiable?
    Eur Heart J. 2025 Feb 28:ehaf042. doi: 10.1093.
    >> Share

  60. STORK S
    Suspected heart failure: a clinical pattern that calls for action.
    Eur Heart J. 2025 Feb 25:ehae846. doi: 10.1093.
    >> Share

  61. ABDELLATIF M, Vasques-Novoa F, Trummer-Herbst V, Durand S, et al
    Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Feb 25:ehaf062. doi: 10.1093.
    >> Share

  62. GREEN PG, Watson WD, Bussmann BM, De Maria GL, et al
    Metabolic flexibility and reverse remodelling of the failing human heart.
    Eur Heart J. 2025 Feb 25:ehaf033. doi: 10.1093.
    >> Share

  63. DOI S, Reddy YNV, Jensen MD, Smith JR, et al
    Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: the CAMEO-DAPA trial.
    Eur Heart J. 2025 Feb 19:ehaf027. doi: 10.1093.
    >> Share

  64. FIORETTI F, Nair AP, Anker SD, Borlaug BA, et al
    Therapeutic left-to-right shunting in heart failure.
    Eur Heart J. 2025 Feb 13:ehaf120. doi: 10.1093.
    >> Share

  65. ANDERSON L, Bayes-Genis A, Bodegard J, Mullin K, et al
    Suspected de novo heart failure in outpatient care: the REVOLUTION HF study.
    Eur Heart J. 2025 Feb 12:ehaf034. doi: 10.1093.
    >> Share

  66. LAKHAL-LITTLETON S
    Anaemia, neurohormonal activation, and myocardial iron depletion in heart failure: can this vicious circle be broken?
    Eur Heart J. 2025 Feb 5:ehae798. doi: 10.1093.
    >> Share

  67. ANGERMANN CE, Sehner S, Gerhardt LMS, Santos-Gallego CG, et al
    Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.
    Eur Heart J. 2025 Feb 5:ehae917. doi: 10.1093.
    >> Share

    January 2025
  68. BUTLER J, Hammonds K, Talha KM, Alhamdow A, et al
    Incident heart failure and recurrent coronary events following acute myocardial infarction.
    Eur Heart J. 2025 Jan 28:ehae885. doi: 10.1093.
    >> Share

  69. PEIKERT A, Vaduganathan M, Claggett BL, Kulac IJ, et al
    Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
    Eur Heart J. 2025 Jan 28:ehaf057. doi: 10.1093.
    >> Share

  70. MATSUMOTO S, Ohno Y, Noda S, Miyamoto J, et al
    Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.
    Eur Heart J. 2025 Jan 28:ehae924. doi: 10.1093.
    >> Share

  71. BAUERSACHS J, Zieroth S, de Boer RA
    The year in cardiovascular medicine 2024: the top 10 papers in heart failure.
    Eur Heart J. 2025 Jan 23:ehaf017. doi: 10.1093.
    >> Share

  72. LIUZZO G, Patrono C
    Weekly Journal Scan: Have we reached the SUMMIT of incretin treatment of heart failure with preserved ejection fraction and obesity?
    Eur Heart J. 2025 Jan 21:ehaf013. doi: 10.1093.
    >> Share

  73. GASPERETTI A, Carrick RT, Protonotarios A, Murray B, et al
    Clinical features and outcomes in carriers of pathogenic desmoplakin variants.
    Eur Heart J. 2025;46:362-376.
    >> Share

  74. ANTONIADES C, Chan K
    Using artificial intelligence to spot heart failure from ECGs: is it prime time?
    Eur Heart J. 2025 Jan 15:ehae906. doi: 10.1093.
    >> Share

  75. DHINGRA LS, Aminorroaya A, Sangha V, Pedroso AF, et al
    Heart failure risk stratification using artificial intelligence applied to electrocardiogram images: a multinational study.
    Eur Heart J. 2025 Jan 13:ehae914. doi: 10.1093.
    >> Share

  76. WILKINSON C, Bhatty A, Batra G, Aktaa S, et al
    Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
    Eur Heart J. 2025;46:190-214.
    >> Share

    December 2024
  77. VAN ESSEN BJ, Emmens JE, Tromp J, Ouwerkerk W, et al
    Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years.
    Eur Heart J. 2024 Dec 30:ehae868. doi: 10.1093.
    >> Share

  78. VAN LOON T, Rijks J, van Koll J, Wolffs J, et al
    Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study.
    Eur Heart J. 2024;45:4953-4964.
    >> Share

  79. FERREIRA JP, Zannad F, Vasques-Novoa F, Neves JS, et al
    Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur Heart J. 2024 Dec 6:ehae864. doi: 10.1093.
    >> Share

  80. CREA F
    Focus on adult congenital heart disease and on the role of inflammation and clonal haematopoiesis in heart failure.
    Eur Heart J. 2024;45:4773-4776.
    >> Share

    November 2024
  81. AI L, de Freitas Germano J, Huang C, Aniag M, et al
    Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364.
    Eur Heart J. 2024 Nov 27:ehae782. doi: 10.1093.
    >> Share

  82. OMEROVIC E, Ramunddal T, Petursson P, Angeras O, et al
    Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry.
    Eur Heart J. 2024 Nov 27:ehae700. doi: 10.1093.
    >> Share

  83. MEYER M
    Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?
    Eur Heart J. 2024 Nov 26:ehae766. doi: 10.1093.
    >> Share

  84. MAZHAR F, Faucon AL, Fu EL, Szummer KE, et al
    Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.
    Eur Heart J. 2024;45:4719-4730.
    >> Share


  85. Correction to: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Eur Heart J. 2024 Nov 18:ehae818. doi: 10.1093.
    >> Share

  86. EL BEZE N, Steg PG
    Heart failure and revascularization: which method to choose and should we even do it?
    Eur Heart J. 2024 Nov 11:ehae715. doi: 10.1093.
    >> Share

  87. WANDEL S, Desai AS, Chen CW, McMurray JJV, et al
    Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trials.
    Eur Heart J. 2024 Nov 9:ehae753. doi: 10.1093.
    >> Share

  88. CREA F
    Evolving therapeutic approaches to aortic stenosis, tricuspid regurgitation, hypertrophic cardiomyopathy, and acute heart failure.
    Eur Heart J. 2024;45:4451-4455.
    >> Share

  89. SEFEROVIC PM, Coats AJS, Filippatos G
    The ESC Textbook of Heart Failure: breaking the new educational frontier.
    Eur Heart J. 2024 Nov 6:ehad897. doi: 10.1093.
    >> Share

    October 2024
  90. PEDICINO D, Vergallo R
    Weekly Journal Scan: RESHAPing potential treatment indications for functional mitral regurgitation in heart failure.
    Eur Heart J. 2024 Oct 29:ehae727. doi: 10.1093.
    >> Share

  91. KARAKASIS P, Pamporis K, Siontis KC, Theofilis P, et al
    Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis.
    Eur Heart J. 2024 Oct 21:ehae694. doi: 10.1093.
    >> Share

  92. TAYLOR J
    New editor-in-chief for European Society of Cardiology heart failure journals.
    Eur Heart J. 2024 Oct 16:ehae644. doi: 10.1093.
    >> Share

  93. MAACK C, Vilahur G, Ruiz-Meana M, Hausenloy D, et al
    New COST Action 'EUropean network to tackle METAbolic alterations in HEART failure' (EU-METAHEART).
    Eur Heart J. 2024 Oct 16:ehae457. doi: 10.1093.
    >> Share

  94. VOLPE M, Galiuto L
    Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2024 Oct 11:ehae679. doi: 10.1093.
    >> Share

  95. CREA F
    New light shed on the treatment of heart failure and on novel therapeutic targets.
    Eur Heart J. 2024;45:3775-3779.
    >> Share

  96. ROSENGREN A
    Loop diuretics in cardiovascular disease: friend or foe?
    Eur Heart J. 2024;45:3850-3852.
    >> Share

    September 2024
  97. TALHA KM, Metra M, Butler J
    Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation.
    Eur Heart J. 2024 Sep 9:ehae544. doi: 10.1093.
    >> Share

  98. HAVERS-BORGERSEN E, Hartwell D, Ekelund C, Butt JH, et al
    Endometriosis and Long-Term Cardiovascular Risk: A Nationwide Danish study.
    Eur Heart J. 2024 Sep 2:ehae563. doi: 10.1093.
    >> Share

    August 2024
  99. BHATT AS, Vaduganathan M
    Implementing Medical Therapy During Worsening Heart Failure.
    Eur Heart J. 2024 Aug 31:ehae566. doi: 10.1093.
    >> Share

  100. TANAKA A, Kida K, Matsue Y, Imai T, et al
    In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.
    Eur Heart J. 2024 Aug 31:ehae561. doi: 10.1093.
    >> Share

  101. PASCUAL-FIGAL D, Nunez J, Perez-Martinez MT, Gonzalez-Juanatey JR, et al
    Colchicine in acutely decompensated heart failure: the COLICA trial.
    Eur Heart J. 2024 Aug 30:ehae538. doi: 10.1093.
    >> Share

  102. TARDIF JC, Ouellette K, Boulet J
    Colchicine improves outcomes in coronary disease, but will it in heart failure?
    Eur Heart J. 2024 Aug 30:ehae612. doi: 10.1093.
    >> Share

  103. MINISTRINI S, Tirandi A
    Von Willebrand factor in inflammation and heart failure: beyond thromboembolic and bleeding risk.
    Eur Heart J. 2024 Aug 28:ehae543. doi: 10.1093.
    >> Share

  104. VON HAEHLING S, Doehner W, Evertz R, Garfias-Veitl T, et al
    Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.
    Eur Heart J. 2024 Aug 26:ehae479. doi: 10.1093.
    >> Share

  105. KITTIPIBUL V, Mentz RJ
    Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?
    Eur Heart J. 2024 Aug 26:ehae490. doi: 10.1093.
    >> Share

  106. REDDY YNV, Melenovsky V, Asokan AK, Haluzik M, et al
    Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction.
    Eur Heart J. 2024 Aug 21:ehae534. doi: 10.1093.
    >> Share

  107. MANG G, Chen J, Sun P, Ma R, et al
    Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps.
    Eur Heart J. 2024 Aug 21:ehae517. doi: 10.1093.
    >> Share

  108. CREA F
    Hot topics in thromboembolic risk prevention, heart failure monitoring, and cardiomyopathy risk stratification.
    Eur Heart J. 2024;45:2899-2903.
    >> Share


  109. Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
    Eur Heart J. 2024 Aug 20:ehae243. doi: 10.1093.
    >> Share

  110. ROSENKRANZ S, Hoeper MM, Maron BA
    Pulmonary hypertension in heart failure: the good, the bad, and the ugly.
    Eur Heart J. 2024 Aug 12:ehae518. doi: 10.1093.
    >> Share

  111. CREA F
    Heart failure and ischaemic heart disease: new challenges and opportunities.
    Eur Heart J. 2024;45:2681-2685.
    >> Share

  112. RIVERO-SANTANA B, Saldana-Garcia J, Caro-Codon J, Zamora P, et al
    Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Eur Heart J. 2024 Aug 6:ehae496. doi: 10.1093.
    >> Share

    July 2024
  113. FAUVEL C, Damy T, Berthelot E, Bauer F, et al
    Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.
    Eur Heart J. 2024 Jul 26:ehae467. doi: 10.1093.
    >> Share

  114. OSTROMINSKI JW, Chatur S, Vaduganathan M
    STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?
    Eur Heart J. 2024 Jul 26:ehae410. doi: 10.1093.
    >> Share

  115. CREA F
    Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves.
    Eur Heart J. 2024;45:2463-2467.
    >> Share

  116. STORK S
    Pulmonary artery pressure-guided heart failure care: the setting matters.
    Eur Heart J. 2024 Jul 19:ehae441. doi: 10.1093.
    >> Share

  117. PEDICINO D, Volpe M
    Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPs.
    Eur Heart J. 2024 Jul 10:ehae427. doi: 10.1093.
    >> Share

  118. OSTROMINSKI JW, Solomon SD, Vaduganathan M
    Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Eur Heart J. 2024 Jul 10:ehae414. doi: 10.1093.
    >> Share

  119. ZANNAD F, Ferreira JP
    Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there.
    Eur Heart J. 2024 Jul 9:ehae399. doi: 10.1093.
    >> Share

  120. CREA F
    A new classification of iron-deficient heart failure, sex-related differences in the management of atrial fibrillation and mitral regurgitation, and an update on the genetics of Brugada syndrome.
    Eur Heart J. 2024;45:2267-2270.
    >> Share

  121. CREA F
    Innovative therapeutic targets in cardio-oncology and a Great Debate in heart failure.
    Eur Heart J. 2024;45:2171-2174.
    >> Share

  122. BOROVAC JA
    Guideline-recommended medical therapy for de novo heart failure with reduced ejection fraction: be patient waiting for reverse remodelling.
    Eur Heart J. 2024 Jul 8:ehae400. doi: 10.1093.
    >> Share

  123. BECHER N, Metzner A, Toennis T, Kirchhof P, et al
    Atrial fibrillation burden: a new outcome predictor and therapeutic target.
    Eur Heart J. 2024 Jul 2:ehae373. doi: 10.1093.
    >> Share

    June 2024
  124. HOLFELD J, Nagele F, Polzl L, Engler C, et al
    Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial.
    Eur Heart J. 2024 Jun 20:ehae341. doi: 10.1093.
    >> Share

  125. VELTMANN C, Duncker D, Doering M, Gummadi S, et al
    Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.
    Eur Heart J. 2024 Jun 12:ehae334. doi: 10.1093.
    >> Share

  126. FRIDAY JM, Cleland JG, Pellicori P, Wolters M, et al
    Loop diuretic utilisation with or without heart failure: impact on prognosis.
    Eur Heart J. 2024 Jun 7:ehae345. doi: 10.1093.
    >> Share

  127. CREA F
    Focus on emerging cancer drugs, artificial intelligence applied to imaging, and a new therapeutic target in heart failure.
    Eur Heart J. 2024;45:1959-1962.
    >> Share

  128. BHAVE S, Rodriguez V, Poterucha T, Mutasa S, et al
    Deep learning to detect left ventricular structural abnormalities in chest X-rays.
    Eur Heart J. 2024;45:2002-2012.
    >> Share

  129. ABBAS N, Haas JA, Xiao K, Fuchs M, et al
    Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo.
    Eur Heart J. 2024;45:2016-2018.
    >> Share


  130. Correction to: Epidemiology of heart failure in young adults: a French nationwide cohort study.
    Eur Heart J. 2024 Jun 4:ehae187. doi: 10.1093.
    >> Share

    May 2024
  131. PACKER M, Cleland JGF, Bauersachs J
    Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 May 28:ehae300. doi: 10.1093.
    >> Share

  132. YANO T, Takeda A, Murayama K
    A hidden cause of middle-aged onset heart failure with preserved ejection fraction: a GTPBP3 variant.
    Eur Heart J. 2024 May 24:ehae309. doi: 10.1093.
    >> Share

  133. FEINSTEIN MJ
    Human Immunology of Heart Failure: Deconstructing Inflammatory Risk.
    Eur Heart J. 2024 May 21:ehae339. doi: 10.1093.
    >> Share

  134. SUN J, Yao J, Olen O, Halfvarson J, et al
    Risk of heart failure in inflammatory bowel disease: a Swedish population-based study.
    Eur Heart J. 2024 May 21:ehae338. doi: 10.1093.
    >> Share


  135. Correction to: Anthracycline therapy induces an early decline of cardiac contractility with transient edema in low risk patients with breast cancer.
    Eur Heart J. 2024;45:1764.
    >> Share

  136. DUBIN RF, Deo R, Ren Y, Wang J, et al
    Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification.
    Eur Heart J. 2024 May 17:ehae288. doi: 10.1093.
    >> Share

  137. AVIERINOS JF, Tribouilloy C, Bursi F, Grigioni F, et al
    Degenerative mitral regurgitation due to flail leaflet: sex-related differences in presentation, management, and outcomes.
    Eur Heart J. 2024 May 16:ehae265. doi: 10.1093.
    >> Share

  138. SHAH SJ, Sharma K, Borlaug BA, Butler J, et al
    Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
    Eur Heart J. 2024 May 13:ehae322. doi: 10.1093.
    >> Share

  139. PACKER M, Anker SD, Butler J, Cleland JGF, et al
    Identification of three mechanistic pathways for iron-deficient heart failure.
    Eur Heart J. 2024 May 11:ehae284. doi: 10.1093.
    >> Share

  140. CLEPHAS PRD, Zwartkruis VW, Malgie J, van Gent MWF, et al
    Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.
    Eur Heart J. 2024 May 11:ehae323. doi: 10.1093.
    >> Share

  141. WANG R, Schiattarella GG
    Tackling metabolic defects in HFpEF.
    Eur Heart J. 2024;45:1494-1496.
    >> Share

    April 2024
  142. NGO LTH, Peng Y, Denman R, Yang I, et al
    Long-term outcomes after hospitalization for atrial fibrillation or flutter.
    Eur Heart J. 2024 Apr 28:ehae204. doi: 10.1093.
    >> Share

  143. JACKSON AM, Goland S, Farhan HA, Yaseen IF, et al
    A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry.
    Eur Heart J. 2024;45:1430-1439.
    >> Share

  144. PALUDAN-MULLER C, Vad OB, Stampe NK, Diederichsen SZ, et al
    Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality.
    Eur Heart J. 2024 Apr 9:ehae216. doi: 10.1093.
    >> Share

  145. CREA F
    The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing.
    Eur Heart J. 2024;45:1183-1187.
    >> Share

  146. RUZIEH M
    Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
    Eur Heart J. 2024;45:1284.
    >> Share

  147. WU VC, Yeh JK, Chen SW, Wu CL, et al
    Syphilis and cardiovascular risk: a Taiwanese registry.
    Eur Heart J. 2024 Apr 3:ehae183. doi: 10.1093.
    >> Share

    March 2024
  148. ALCOCER-GAMBA MA, Alvarez-Sangabriel A, de la Parra-Calderon JA
    Management of heart failure in Mexico: challenges and opportunities.
    Eur Heart J. 2024 Mar 29:ehae059. doi: 10.1093.
    >> Share

  149. PEDICINO D, Volpe M
    Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction.
    Eur Heart J. 2024 Mar 28:ehae167. doi: 10.1093.
    >> Share

  150. WYLD M, Webster AC
    Myocardial infarction and stroke in patients with kidney failure: can we do better?
    Eur Heart J. 2024 Mar 27:ehae153. doi: 10.1093.
    >> Share

  151. SCHUERMANS A, Vlasschaert C, Nauffal V, Cho SMJ, et al
    Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias.
    Eur Heart J. 2024;45:791-805.
    >> Share

  152. CLELAND JGF, Kalra PA, Pellicori P, Graham FJ, et al
    Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
    Eur Heart J. 2024 Mar 6:ehae086. doi: 10.1093.
    >> Share

  153. CHAIX MA, Dore A, Mondesert B, Mongeon FP, et al
    Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial.
    Eur Heart J. 2024 Mar 6:ehad890. doi: 10.1093.
    >> Share

  154. SAYOUR NV, Paal AM, Ameri P, Meijers WC, et al
    Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
    Eur Heart J. 2024 Mar 5:ehae105. doi: 10.1093.
    >> Share

  155. MURARU D, Badano LP, Hahn RT, Lang RM, et al
    Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.
    Eur Heart J. 2024 Mar 5:ehae088. doi: 10.1093.
    >> Share


  156. Correction to: Conventional heart failure therapy in cardiac ATTR amyloidosis.
    Eur Heart J. 2024 Mar 1:ehae140. doi: 10.1093.
    >> Share

    February 2024
  157. ZURKAN D, Pitt B, Edelmann F
    Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?
    Eur Heart J. 2024 Feb 6:ehae040. doi: 10.1093.
    >> Share

    January 2024
  158. BERNARDO MC, Carvalho SS, Moreira I
    Massive myocardial calcification as an aetiology of heart failure.
    Eur Heart J. 2024 Jan 23:ehae009. doi: 10.1093.
    >> Share

  159. BAUERSACHS J, de Boer RA, Zieroth S
    The year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2024 Jan 18:ehad878. doi: 10.1093.
    >> Share

  160. GALIUTO L, Volpe M
    A new RNA-interference based strategy is associated with mild beneficial effects in patients with heart failure due to cardiac amyloidosis.
    Eur Heart J. 2024 Jan 18:ehae015. doi: 10.1093.
    >> Share

  161. DOEHNER W, Akyea RK, Ntaios G
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad761. doi: 10.1093.
    >> Share

  162. BUTT JH, McMurray JJV
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad764. doi: 10.1093.
    >> Share

  163. AHN HJ, An HY, Ryu G, Lim J, et al
    Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
    Eur Heart J. 2024 Jan 17:ehad869. doi: 10.1093.
    >> Share

  164. PELLICORI P, Hunter D, Ei Khin HH, Cleland JGF, et al
    How to diagnose and treat venous congestion in heart failure.
    Eur Heart J. 2024 Jan 9:ehad883. doi: 10.1093.
    >> Share

  165. ORAII A, Healey JS, Kowalik K, Pandey AK, et al
    Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.
    Eur Heart J. 2024 Jan 9:ehad811. doi: 10.1093.
    >> Share

  166. KAMBIC T, Lavie CJ, Eijsvogels TMH
    Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction.
    Eur Heart J. 2024 Jan 8:ehad856. doi: 10.1093.
    >> Share

    December 2023

  167. Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
    Eur Heart J. 2023 Dec 21:ehad855. doi: 10.1093.
    >> Share

  168. ABU-OWN H, Webb I, Okonko DO
    Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes.
    Eur Heart J. 2023;44:5092-5094.
    >> Share

  169. KRAMARENKO D, Walsh R
    Emery-Dreifuss muscular dystrophy: a closer look at cardiac complications.
    Eur Heart J. 2023;44:5074-5076.
    >> Share

  170. LI XM, Zhu XJ, Jing ZC
    Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure.
    Eur Heart J. 2023 Dec 16:ehad822. doi: 10.1093.
    >> Share

  171. MULLER FS, Aherrahrou Z, Grasshoff H, Heidorn MW, et al
    Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
    Eur Heart J. 2023;44:4935-4949.
    >> Share

  172. MEHRA MR, Castagna F, Butler J
    The transformative potential of left ventricular assist devices in advanced heart failure: no more a therapeutic orphan.
    Eur Heart J. 2023 Dec 11:ehad555. doi: 10.1093.
    >> Share

  173. KHAN MS, Usman MS, Van Spall HGC, Greene SJ, et al
    Endpoint adjudication in cardiovascular clinical trials.
    Eur Heart J. 2023;44:4835-4846.
    >> Share

  174. WESTWOOD M, Almeida AG, Barbato E, Delgado V, et al
    Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC). With the contribution of the European Association of Cardiovascular Imaging (EACVI), and the support of the Association of Cardiovascul
    Eur Heart J. 2023;44:4771-4780.
    >> Share

    November 2023
  175. SCHMITTO JD, Shaw S, Garbade J, Gustafsson F, et al
    Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry.
    Eur Heart J. 2023 Nov 30:ehad658. doi: 10.1093.
    >> Share


  176. Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of
    Eur Heart J. 2023 Nov 23:ehad613. doi: 10.1093.
    >> Share

  177. CREA F
    Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets.
    Eur Heart J. 2023;44:4607-4611.
    >> Share

  178. TOMII D, Praz F, Windecker S
    Guideline directed medical therapy in patients with heart failure undergoing transcatheter edge-to-edge mitral valve repair: unfulfilled premise.
    Eur Heart J. 2023 Nov 15:ehad678. doi: 10.1093.
    >> Share

  179. HENRY CM, Oseran AS, Zheng Z, Dong H, et al
    Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States.
    Eur Heart J. 2023 Nov 11:ehad772. doi: 10.1093.
    >> Share

  180. JESSEN N, Mocumbi AO, Sliwa K
    Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent.
    Eur Heart J. 2023 Nov 9:ehad742. doi: 10.1093.
    >> Share

  181. WERT L, Falk V, Potapov EV
    Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach.
    Eur Heart J. 2023 Nov 9:ehad750. doi: 10.1093.
    >> Share

  182. KIYUNA LA, Candido DS, Bechara LRG, Jesus ICG, et al
    4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification.
    Eur Heart J. 2023 Nov 7:ehad662. doi: 10.1093.
    >> Share

  183. SLUIJTER JPG, Xiao J
    Post-translational modifications upon mitochondrial dysfunction in heart failure.
    Eur Heart J. 2023 Nov 6:ehad710. doi: 10.1093.
    >> Share

  184. INCIARDI RM, Solomon SD
    Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure.
    Eur Heart J. 2023 Nov 3:ehad747. doi: 10.1093.
    >> Share

    October 2023
  185. RESTIVO A, Paglianiti DA, D'Amario D
    Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept.
    Eur Heart J. 2023 Oct 26:ehad730. doi: 10.1093.
    >> Share

  186. LIUZZO G, Patrono C
    Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Oct 25:ehad674. doi: 10.1093.
    >> Share

  187. CREA F
    Innovative trials in heart failure, dyslipidaemias, and sinus node dysfunction.
    Eur Heart J. 2023;44:4203-4207.
    >> Share

  188. PANDEY A, Kolkailah AA, Cosentino F, Cannon CP, et al
    Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
    Eur Heart J. 2023 Oct 21:ehad639. doi: 10.1093.
    >> Share

  189. DENIAU B, Costanzo MR, Sliwa K, Asakage A, et al
    Acute heart failure: current pharmacological treatment and perspectives.
    Eur Heart J. 2023 Oct 18:ehad617. doi: 10.1093.
    >> Share

  190. PEDICINO D, Volpe M
    Atrial fibrillation ablation improves outcomes in patients with end-stage heart failure: is it all gold the glitter in the CASTLE?
    Eur Heart J. 2023 Oct 17:ehad675. doi: 10.1093.
    >> Share

  191. CAI A, Qiu W, Xia S, Zhou Y, et al
    Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.
    Eur Heart J. 2023 Oct 4:ehad619. doi: 10.1093.
    >> Share

  192. CREA F
    Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses.
    Eur Heart J. 2023;44:3487-3491.
    >> Share

    September 2023
  193. BORLAUG BA, Schaff HV, Asirvatham SJ, Koepp KE, et al
    Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study.
    Eur Heart J. 2023 Sep 22:ehad620. doi: 10.1093.
    >> Share

  194. MOHANTY S, La Fazia VM, Natale A
    The Antwerp score: is this the 'new hope on the horizon'?
    Eur Heart J. 2023;44:3336-3338.
    >> Share

  195. PANDEY AK, Bhatt DL, Pandey A, Marx N, et al
    Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Sep 7:ehad389. doi: 10.1093.
    >> Share

  196. CREA F
    Hot topics in congenital heart disease: tetralogy of Fallot, Ross operation, immunodeficiency, cardiac arrest, and end-stage heart failure.
    Eur Heart J. 2023;44:3201-3204.
    >> Share

  197. LADOUCEUR M
    Congenitally corrected transposition of the great arteries: have we shifted the disease 'trajectory?
    Eur Heart J. 2023;44:3292-3294.
    >> Share

  198. ANGERMANN CE, Ertl G
    Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
    Eur Heart J. 2023 Sep 6:ehad525. doi: 10.1093.
    >> Share

  199. BROWNELL NK, Fonarow GC
    Hospitalization for heart failure requires a PROMPT response.
    Eur Heart J. 2023 Sep 6:ehad444. doi: 10.1093.
    >> Share

    August 2023
  200. GHAZI L, Yamamoto Y, Fuery M, O'Connor K, et al
    Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial.
    Eur Heart J. 2023 Aug 31:ehad512. doi: 10.1093.
    >> Share

  201. LEONG DP, Joseph P, McMurray JJV, Rouleau J, et al
    Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries.
    Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093.
    >> Share

  202. CANNIE DE, Syrris P, Protonotarios A, Bakalakos A, et al
    Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure.
    Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093.
    >> Share

  203. MCALISTER FA
    Frailty: A new Vital Sign in Heart Failure Comes of age.
    Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093.
    >> Share

  204. NASER JA, Lee E, Scott CG, Kennedy AM, et al
    Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications.
    Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093.
    >> Share

  205. VARSHNEY AS, Shah M, Vemulapalli S, Kosinski A, et al
    Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry.
    Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093.
    >> Share

  206. MERKELY B, Hatala R, Wranicz JK, Duray G, et al
    Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial.
    Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093.
    >> Share

  207. LINDE C
    The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction.
    Eur Heart J. 2023 Aug 26:ehad588. doi: 10.1093.
    >> Share

  208. PONIKOWSKI P, Mentz RJ, Hernandez AF, Butler J, et al
    Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
    Eur Heart J. 2023 Aug 26:ehad586. doi: 10.1093.
    >> Share

  209. BUENO H, Packer M
    Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma?
    Eur Heart J. 2023 Aug 25:ehad560. doi: 10.1093.
    >> Share

  210. MEEKERS E, Dauw J, Martens P, Dhont S, et al
    Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial.
    Eur Heart J. 2023 Aug 25:ehad557. doi: 10.1093.
    >> Share

  211. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2023 Aug 25:ehad195. doi: 10.1093.
    >> Share

  212. WU J, Nadarajah R, Nakao YM, Nakao K, et al
    Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation.
    Eur Heart J. 2023 Aug 25:ehad571. doi: 10.1093.
    >> Share

  213. BAUERSACHS J, Soltani S
    Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
    Eur Heart J. 2023 Aug 23:ehad540. doi: 10.1093.
    >> Share

  214. BANERJEE M, Maisnam I, Pal R, Mukhopadhyay S, et al
    Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Eur Heart J. 2023 Aug 22:ehad522. doi: 10.1093.
    >> Share

  215. VAN DISSEL AC, Opotowsky AR, Burchill LJ, Aboulhosn J, et al
    End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study.
    Eur Heart J. 2023 Aug 18:ehad511. doi: 10.1093.
    >> Share

  216. CREA F
    Late breaking trials in heart failure.
    Eur Heart J. 2023;44:2877-2882.
    >> Share

  217. MARTENS P, Testani J, Damman K
    Prevention and treatment of diuretic resistance in acute heart failure: when to use which combination of diuretics?
    Eur Heart J. 2023;44:2978-2981.
    >> Share

  218. CHENG RK, Cuddy SAM
    Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?
    Eur Heart J. 2023;44:2908-2910.
    >> Share

  219. BAYES-GENIS A, Pascual-Figal D
    Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring.
    Eur Heart J. 2023;44:2963-2965.
    >> Share

  220. NADARAJAH R, Nakao YM, Wu J, Gale CP, et al
    Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF.
    Eur Heart J. 2023 Aug 3:ehad440. doi: 10.1093.
    >> Share

  221. LIN GM, Tsai KZ, Lavie CJ
    Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness?
    Eur Heart J. 2023 Aug 2:ehad503. doi: 10.1093.
    >> Share

  222. ROHDE LE, McMurray JJV
    REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed.
    Eur Heart J. 2023 Aug 1:ehad488. doi: 10.1093.
    >> Share

    July 2023
  223. PEDICINO D, Volpe M
    New evidence supporting haemodynamics-guided remote management of congestion in heart failure.
    Eur Heart J. 2023 Jul 21:ehad435. doi: 10.1093.
    >> Share

  224. VERGALLO R, Patrono C
    Heart failure and socioeconomic status: global differences and inequalities.
    Eur Heart J. 2023 Jul 15:ehad410. doi: 10.1093.
    >> Share

  225. GREENE SJ, Fonarow GC
    Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jul 5:ehad427. doi: 10.1093.
    >> Share


  226. Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023 Jul 3:ehad406. doi: 10.1093.
    >> Share

    June 2023
  227. BERGONTI M, Ascione C, Marcon L, Pambrun T, et al
    Left ventricular functional recovery after atrial fibrillation catheter ablation in heart failure: a prediction model.
    Eur Heart J. 2023 Jun 30:ehad428. doi: 10.1093.
    >> Share

  228. KOEHLER F, Hindricks G
    Is telemonitoring for heart failure ready after a journey longer than two decades?
    Eur Heart J. 2023 Jun 27:ehad395. doi: 10.1093.
    >> Share

  229. WITSCH J, Kasner SE
    Redefining the role of heart failure in stroke.
    Eur Heart J. 2023 Jun 26:ehad360. doi: 10.1093.
    >> Share

  230. YANG M, Kondo T, Butt JH, Abraham WT, et al
    Stroke in patients with heart failure and reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jun 26:ehad338. doi: 10.1093.
    >> Share

  231. CREA F
    Challenges and opportunities in the management of acute heart failure and cardiac amyloidosis.
    Eur Heart J. 2023;44:2135-2139.
    >> Share

  232. ARNOTT C, Neal B
    Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023;44:2184-2186.
    >> Share

  233. TOLOMEO P, Butt JH, Kondo T, Campo G, et al
    Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.
    Eur Heart J. 2023;44:2202-2212.
    >> Share

  234. PEDICINO D, Vergallo R
    Long-lasting effects of transcatheter repair of secondary mitral regurgitation: the latest lesson from COAPT trial.
    Eur Heart J. 2023 Jun 14:ehad349. doi: 10.1093.
    >> Share

  235. JANKOWSKA EA, Ponikowski P
    Acyl-ghrelin therapy for heart failure: already a novel inotrope or even more?
    Eur Heart J. 2023;44:2026-2028.
    >> Share

  236. CREA F
    Addressing the pandemic of heart failure: old and new therapeutic opportunities.
    Eur Heart J. 2023;44:1961-1964.
    >> Share

  237. MARTENS P, Verbrugge FH, Dauw J, Nijst P, et al
    Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.
    Eur Heart J. 2023;44:1995-2005.
    >> Share

  238. MAHMOOD SS, Riedell PA, Feldman S, George G, et al
    Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
    Eur Heart J. 2023;44:2029-2042.
    >> Share

  239. MARTENS P, Yu S, Larive B, Borlaug BA, et al
    Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.
    Eur Heart J. 2023;44:1979-1991.
    >> Share

  240. CAMPBELL RT, Docherty KF
    Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?
    Eur Heart J. 2023;44:2006-2008.
    >> Share

  241. MARX N, Muller-Wieland D
    SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world.
    Eur Heart J. 2023 Jun 8:ehad282. doi: 10.1093.
    >> Share

  242. FU EL, Patorno E, Everett BM, Vaduganathan M, et al
    Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Eur Heart J. 2023 Jun 1:ehad273. doi: 10.1093.
    >> Share

    May 2023

  243. Correction to: The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2023 May 24:ehad307. doi: 10.1093.
    >> Share

  244. BUTT JH, Kondo T, Yang M, Jhund PS, et al
    Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023 May 23:ehad276. doi: 10.1093.
    >> Share

  245. CHATUR S, Vaduganathan M, Claggett B, Vardeny O, et al
    Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Eur Heart J. 2023 May 23:ehad283. doi: 10.1093.
    >> Share

  246. BORLAUG BA, Testani JM
    SGLT2 inhibitors and Diuretics in Heart Failure: Clicking Reset on the Renal Volume Setpoint?
    Eur Heart J. 2023 May 23:ehad345. doi: 10.1093.
    >> Share

  247. ADAMO M, Pagnesi M, Mebazaa A, Davison B, et al
    NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial.
    Eur Heart J. 2023 May 22:ehad335. doi: 10.1093.
    >> Share

  248. IOANNOU A, Massa P, Patel RK, Razvi Y, et al
    Conventional heart failure therapy in cardiac ATTR amyloidosis.
    Eur Heart J. 2023 May 22:ehad347. doi: 10.1093.
    >> Share

  249. SCHOLTE NTB, Gurgoze MT, Aydin D, Theuns DAMJ, et al
    Telemonitoring for heart failure: a meta-analysis.
    Eur Heart J. 2023 May 22:ehad280. doi: 10.1093.
    >> Share

  250. CLEPHAS PRD, Radhoe SP, Boersma E, Gregson J, et al
    Efficacy of Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Meta-Analysis of Three Randomized Controlled Trials.
    Eur Heart J. 2023 May 21:ehad346. doi: 10.1093.
    >> Share

  251. VADUGANATHAN M, Mentz RJ, Claggett BL, Miao ZM, et al
    Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
    Eur Heart J. 2023 May 21:ehad344. doi: 10.1093.
    >> Share

  252. ERN YEOH S, Osmanska J, Petrie MC, Brooksbank KJM, et al
    Dapagliflozin versus metolazone in heart failure resistant to loop diuretics.
    Eur Heart J. 2023 May 21:ehad341. doi: 10.1093.
    >> Share

  253. DAMMAN K
    Risk of knowing too much: the tricky case of estimated glomerular filtration rate and treatment decisions in heart failure.
    Eur Heart J. 2023 May 20:ehad284. doi: 10.1093.
    >> Share

  254. MULLENS W, Schulze PC, Westphal J, Bogoviku J, et al
    Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice.
    Eur Heart J. 2023 May 19:ehad266. doi: 10.1093.
    >> Share


  255. Corrigendum to: Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
    Eur Heart J. 2023 May 8:ehad272. doi: 10.1093.
    >> Share

  256. CREA F
    Heart failure with preserved ejection fraction: innovative diagnostic approaches and therapeutic targets.
    Eur Heart J. 2023;44:1481-1485.
    >> Share

  257. LEHTONEN J, Uusitalo V, Poyhonen P, Mayranpaa MI, et al
    Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.
    Eur Heart J. 2023;44:1495-1510.
    >> Share

  258. LEE SY, Chang S, Youn JC
    Successful management of aortic root thrombosis in a patient with Heartmate 3.
    Eur Heart J. 2023;44:1578.
    >> Share

    April 2023
  259. XIN Y, Li J, Li H
    Combination diuretic therapy in acute heart failure.
    Eur Heart J. 2023 Apr 21:ehad189. doi: 10.1093.
    >> Share

  260. TRULLAS JC, Casado J, Morales-Rull JL
    Combination diuretic therapy in acute heart failure.
    Eur Heart J. 2023 Apr 21:ehad217. doi: 10.1093.
    >> Share


  261. Erratum to: Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
    Eur Heart J. 2023 Apr 20:ehad232. doi: 10.1093.
    >> Share

  262. JALLOH MB, Granger CB, Fonarow GC, Van Spall HGC, et al
    Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure.
    Eur Heart J. 2023 Apr 15:ehad150. doi: 10.1093.
    >> Share

  263. SHERROD CF, Farr SL, Sauer AJ
    Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?
    Eur Heart J. 2023 Apr 12:ehad169. doi: 10.1093.
    >> Share

  264. VAN VELDHUISEN DJ, Bauersachs J
    Digitalis in heart failure: declining use and ongoing outcome trials.
    Eur Heart J. 2023 Apr 8:ehad185. doi: 10.1093.
    >> Share

  265. CREA F
    The link among heart failure, chronic kidney disease, and cancer: new light shed on the complex patient.
    Eur Heart J. 2023;44:1099-1102.
    >> Share

    March 2023
  266. LAM CSP, Ho JE
    Do we need dedicated heart failure with preserved ejection fraction clinics?
    Eur Heart J. 2023 Mar 29:ehad172. doi: 10.1093.
    >> Share

  267. SATO R, von Haehling S
    Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?
    Eur Heart J. 2023 Mar 22:ehad079. doi: 10.1093.
    >> Share

  268. BUTT JH, Petrie MC, Jhund PS, Sattar N, et al
    Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.
    Eur Heart J. 2023 Mar 22:ehad083. doi: 10.1093.
    >> Share

  269. PACKER M, Siddiqi TJ, Butler J
    Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
    Eur Heart J. 2023 Mar 21:ehad158. doi: 10.1093.
    >> Share

  270. LIUZZO G, Volpe M
    TRANSFORM-HF closes the loop on diuretic therapy in heart failure.
    Eur Heart J. 2023 Mar 21:ehad124. doi: 10.1093.
    >> Share

  271. DIAZ-CANESTRO C, Ng HF, Yiu KH, Montero D, et al
    Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
    Eur Heart J. 2023 Mar 16:ehad130. doi: 10.1093.
    >> Share

  272. VERWERFT J, Soens L, Wynants J, Meysman M, et al
    Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic.
    Eur Heart J. 2023 Mar 16:ehad141. doi: 10.1093.
    >> Share

  273. PEDICINO D, Volpe M
    Improving care for heart failure patients by COACHing clinicians to use decision-support tools.
    Eur Heart J. 2023 Mar 16:ehad097. doi: 10.1093.
    >> Share

  274. RAO VN, Giczewska A, Chiswell K, Felker GM, et al
    Long-term outcomes of phenoclusters in severe tricuspid regurgitation.
    Eur Heart J. 2023 Mar 16:ehad133. doi: 10.1093.
    >> Share

  275. LUND LH, Hage C, Pironti G, Thorvaldsen T, et al
    Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.
    Eur Heart J. 2023 Mar 14:ehad100. doi: 10.1093.
    >> Share

  276. TAYLOR RS, Dalal HM, Zwisler AD
    Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of care?
    Eur Heart J. 2023 Mar 11:ehad118. doi: 10.1093.
    >> Share

  277. VERELST FR, Van Craenenbroeck EM, Gevaert AB
    Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
    Eur Heart J. 2023 Mar 9:ehad131. doi: 10.1093.
    >> Share

  278. SHEMESH E, Chevli PA, Islam T, German CA, et al
    Circulating ketone bodies and cardiovascular outcomes: the MESA study.
    Eur Heart J. 2023 Mar 6:ehad087. doi: 10.1093.
    >> Share

  279. KAPELIOS CJ, Benson L, Crespo-Leiro MG, Anker SD, et al
    Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
    Eur Heart J. 2023 Mar 4:ehad109. doi: 10.1093.
    >> Share

    February 2023
  280. VOLPE M, Gallo G, Rubattu S
    Endocrine functions of the heart: from bench to bedside.
    Eur Heart J. 2023;44:643-655.
    >> Share

  281. WOUTERS PC, van de Leur RR, Vessies MB, van Stipdonk AMW, et al
    Electrocardiogram-based deep learning improves outcome prediction following cardiac resynchronization therapy.
    Eur Heart J. 2023;44:680-692.
    >> Share

    January 2023
  282. MARK PB, Carrero JJ, Matsushita K, Sang Y, et al
    Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
    Eur Heart J. 2023 Jan 24:ehac825. doi: 10.1093.
    >> Share

    December 2022
  283. EL-CHOULI M, Meddis A, Christensen DM, Gerds TA, et al
    Lifetime risk of comorbidity in patients with simple congenital heart disease: a Danish nationwide study.
    Eur Heart J. 2022 Dec 7:ehac727. doi: 10.1093.
    >> Share

    November 2022
  284. SCOTTI A, Coisne A, Taramasso M, Granada JF, et al
    Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation.
    Eur Heart J. 2022 Nov 29:ehac735. doi: 10.1093.
    >> Share

  285. HAXHA S, Halili A, Malmborg M, Pedersen-Bjergaard U, et al
    Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry.
    Eur Heart J. 2022 Nov 26:ehac662. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016